Digital x-ray and bone densitometry developer Schick Technologies of Long Island City, NY, is facing several class-action complaints filed by its shareholders, according to Eli Schick, director of investor relations. The complaints, brought this month by
Digital x-ray and bone densitometry developer Schick Technologies of Long Island City, NY, is facing several class-action complaints filed by its shareholders, according to Eli Schick, director of investor relations. The complaints, brought this month by several law firms, claim that Schick knowingly misstated its financial condition before announcing on Dec. 10 that it would take a one-time charge of $5 million against earnings for its third quarter 1998, ending December (SCAN 1/14/99).
In more positive Schick news, the company received a patent for its accuDEXA bone densitometer on Jan. 8. The Food and Drug Administration cleared the unit in December 1997 (SCAN 1/21/98), and Schick has sold about 2500 of the densitometers. AccuDEXA is priced under $13,000.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
2 Commerce Drive
Cranbury, NJ 08512